Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Hope Rugo, MD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    AddressMZ, 1600 Divisadero
    Phone415-353-7070

       Biography 
       Education and Training
      University of California, San FranciscoPost-Doc Fellow/Scholar Medicine (Cancer Research Institute)1989
      University of California, San FranciscoResidency School of Medicine
      University of PennsylvaniaM.D.School of Medicine1984

       Overview 
       Overview
      Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

      Dr. Rugo is the Director of the Breast Oncology Clinical Trials Program, and is the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer. In addition, Dr. Rugo is working on studies to evaluate cognitive function in women receiving chemotherapy for breast cancer, as well as novel ways to reduce toxicity from therapy. Dr. Rugo has established collaborations with a number of other large academic medical centers for the purpose of expanding the novel therapies that are available for our patients, including herbal agents that appear to have an antitumor effect in the laboratory. She is an active member of the national cooperative group, CALGB, and a is a founding member of the Breast Cancer Research Consortium, as well as serving as an investigator in the UCSF Breast SPORE (the Bay Area Specialized Program of Research Excellence in Breast Cancer). Dr. Rugo teaches medical students and physicians, and regularly lectures locally, nationally and internationally on subjects relating to the treatment of breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families and friends from throughout the bay area.

      Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990. In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo has been recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Gianini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intra-mural award. In 2006, she was honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.

      Outside of work, Dr. Rugo spends time with her two children, Philip and Alyssa-Faith, and her husband Martin. Her outside interests include bicycling, hiking, travel with her family and playing the flute.


       ORNG Applications 
       Websites
       In The News
       Awarded Grants
       Global Health
       More Info

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Miller KD, Althouse SK, Nabell L, Rugo H, Carey L, Kimmick G, Jones DR, Merino MJ, Steeg PS. A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. Breast Cancer Res Treat. 2014 Nov; 148(1):99-106.
        View in: PubMed
      2. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014 Oct; 23(5):489-502.
        View in: PubMed
      3. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol. 2014 Oct; 25(10):1871-88.
        View in: PubMed
      4. Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol. 2014 Dec; 25(12):2357-62.
        View in: PubMed
      5. Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O'Connor B, Myerson R, Stauffer P, Hsu IC, Diederich C, Straube W, Boss MK, Boico A, Craciunescu O, Maccarini P, Needham D, Borys N, Blackwell KL, Dewhirst MW. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia. 2014 Aug; 30(5):285-94.
        View in: PubMed
      6. Rugo HS, Aapro M. Reply to the letter to the editor 'Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer' Tannock and Pond. Ann Oncol. 2014 Oct; 25(10):2096-8.
        View in: PubMed
      7. Rugo HS. Hormone therapy in premenopausal women with early-stage breast cancer. N Engl J Med. 2014 Jul 10; 371(2):175-6.
        View in: PubMed
      8. Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, Bertozzi CR, Weaver VM. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature. 2014 Jul 17; 511(7509):319-25.
        View in: PubMed
      9. Kaufman PA, Bloom KJ, Burris H, Gralow JR, Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Yoo B, Brammer MG, Vogel CL. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer. 2014 Sep 1; 120(17):2657-64.
        View in: PubMed
      10. Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50.
        View in: PubMed
      11. Tripathy D, Rugo HS, Kaufman PA, Swain S, O'Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S. The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer. 2014; 14(1):307.
        View in: PubMed
      12. Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C, Ulcickas Yood M. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014 May 27; 110(11):2756-64.
        View in: PubMed
      13. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9.
        View in: PubMed
      14. Yardley DA, Kaufman PA, Brufsky A, Yood MU, Rugo H, Mayer M, Quah C, Yoo B, Tripathy D. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2014 Jun; 145(3):725-34.
        View in: PubMed
      15. Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T, Burris HA. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol. 2014 Apr; 25(4):808-15.
        View in: PubMed
      16. Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014 Jul; 25(7):1328-33.
        View in: PubMed
      17. Danesh M, Belkora J, Volz S, Rugo HS. Informational needs of patients with metastatic breast cancer: what questions do they ask, and are physicians answering them? J Cancer Educ. 2014 Mar; 29(1):175-80.
        View in: PubMed
      18. Hurria A, Wildes T, Blair SL, Browner IS, Cohen HJ, Deshazo M, Dotan E, Edil BH, Extermann M, Ganti AK, Holmes HM, Jagsi R, Karlekar MB, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Weir AB, Bergman MA, Sundar H. Senior adult oncology, version 2.2014. J Natl Compr Canc Netw. 2014 Jan 1; 12(1):82-126.
        View in: PubMed
      19. Parikh PM, Gupta S, Dawood S, Rugo H, Bhattacharyya GS, Agarwal A, Chacko R, Sahoo TP, Babu G, Agarwal S, Munshi A, Goswami C, Smruti BK, Bondarde S, Desai C, Rajappa S, Somani N, Singh M, Nimmagadda R, Pavitran K, Mehta A, Parmar V, Desai S, Nair R, Doval D. ICON 2013: Practical consensus recommendations for hormone receptor-positive Her2-negative advanced or metastatic breastcancer. Indian J Cancer. 2014 Jan-Mar; 51(1):73-9.
        View in: PubMed
      20. Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart M. Everolimus plus exemestane as first-line therapy in HR(+), HER2 (-) advanced breast cancer in BOLERO-2. Breast Cancer Res Treat. 2014 Feb; 143(3):459-67.
        View in: PubMed
      21. Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M. Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2. Clin Breast Cancer. 2013 Dec; 13(6):421-432.e8.
        View in: PubMed
      22. Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Adv Ther. 2013 Oct; 30(10):870-84.
        View in: PubMed
      23. Rugo HS. New developments in metastatic breast cancer: introduction. Clin Adv Hematol Oncol. 2013 Oct; 11 Suppl 16(10):4-7.
        View in: PubMed
      24. Vahdat LT, Rugo HS, Perez EA. New developments in metastatic breast cancer: general discussion. Clin Adv Hematol Oncol. 2013 Oct; 11 Suppl 16(10):16-7.
        View in: PubMed
      25. Rugo HS. New developments in metastatic breast cancer: introduction. Clin Adv Hematol Oncol. 2013 Oct; 11(10 Suppl 16):4-7.
        View in: PubMed
      26. Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M. Myeloid growth factors. J Natl Compr Canc Netw. 2013 Oct 1; 11(10):1266-90.
        View in: PubMed
      27. Rugo HS, Brufsky AM, Ulcickas Yood M, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye OO, Yardley DA. Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Oct; 141(3):461-70.
        View in: PubMed
      28. Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA. Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Curr Med Res Opin. 2013 Nov; 29(11):1463-73.
        View in: PubMed
      29. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013 Oct 1; 19(19):5505-12.
        View in: PubMed
      30. Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart M. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer. 2013 Aug; 49(12):2621-32.
        View in: PubMed
      31. André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013 Jul 1; 19(13):3693-702.
        View in: PubMed
      32. Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist. 2013; 18(5):501-10.
        View in: PubMed
      33. Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):411-9.
        View in: PubMed
      34. Burris HA, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013 May 15; 119(10):1908-15.
        View in: PubMed
      35. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 1; 19(11):2817-23.
        View in: PubMed
      36. Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res. 2013 May 15; 19(10):2745-54.
        View in: PubMed
      37. Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst. 2013 May 1; 105(9):654-63.
        View in: PubMed
      38. Grunberg SM, Slusher B, Rugo HS. Emerging treatments in chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2013 Feb; 11(2 Suppl 1):1-18; quiz 2 p following 18.
        View in: PubMed
      39. Vandergrift JL, Niland JC, Theriault RL, Edge SB, Wong YN, Loftus LS, Breslin TM, Hudis CA, Javid SH, Rugo HS, Silver SM, Lepisto EM, Weeks JC. Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst. 2013 Jan 16; 105(2):104-12.
        View in: PubMed
      40. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9.
        View in: PubMed
      41. Chien AJ, Rugo HS. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(1):1-12.
        View in: PubMed
      42. Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res. 2013 Jan 1; 73(1):30-40.
        View in: PubMed
      43. Keck S, Glencer AC, Rugo HS. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer. Future Oncol. 2012 Nov; 8(11):1383-96.
        View in: PubMed
      44. Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012; 14(5):R129.
        View in: PubMed
      45. Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN. Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol. 2012 Oct 1; 30(28):3444-7.
        View in: PubMed
      46. Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardley DA. Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat. 2012 Oct; 135(3):875-83.
        View in: PubMed
      47. Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, Krop IE, Girish S, Friberg LE, Gupta M. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2012 Oct; 70(4):591-601.
        View in: PubMed
      48. Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M. The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. Breast Cancer Res Treat. 2012 Aug; 134(3):1327-35.
        View in: PubMed
      49. Niemasik EE, Letourneau J, Dohan D, Katz A, Melisko M, Rugo H, Rosen M. Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors. J Cancer Surviv. 2012 Sep; 6(3):324-32.
        View in: PubMed
      50. Rugo HS, Keck S. Reversing hormone resistance: have we found the golden key? J Clin Oncol. 2012 Aug 1; 30(22):2707-9.
        View in: PubMed
      51. Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS. The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis. 2012 Oct; 29(7):807-19.
        View in: PubMed
      52. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20; 30(21):2585-92.
        View in: PubMed
      53. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012 Jul 20; 30(21):2615-23.
        View in: PubMed
      54. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012 Sep 10; 30(26):3234-41.
        View in: PubMed
      55. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9.
        View in: PubMed
      56. Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, Chang HY, Werb Z. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov. 2012 Jul; 2(7):638-51.
        View in: PubMed
      57. McCann B, Miaskowski C, Koetters T, Baggott C, West C, Levine JD, Elboim C, Abrams G, Hamolsky D, Dunn L, Rugo H, Dodd M, Paul SM, Neuhaus J, Cooper B, Schmidt B, Langford D, Cataldo J, Aouizerat BE. Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. J Pain. 2012 May; 13(5):425-37.
        View in: PubMed
      58. Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba SG. Antiemesis. J Natl Compr Canc Netw. 2012 Apr; 10(4):456-85.
        View in: PubMed
      59. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van't Veer L, Viale G, Krop I, Winer E. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012 Jun; 21(3):242-52.
        View in: PubMed
      60. Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, Rivera R, Duenne A, Bousfoul N, Yardley DA. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat. 2012 Jun; 133(3):1067-75.
        View in: PubMed
      61. Rugo HS. Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning? J Clin Oncol. 2012 Mar 20; 30(9):898-901.
        View in: PubMed
      62. Hurria A, Browner IS, Cohen HJ, Denlinger CS, deShazo M, Extermann M, Ganti AK, Holland JC, Holmes HM, Karlekar MB, Keating NL, McKoy J, Medeiros BC, Mrozek E, O'Connor T, Petersdorf SH, Rugo HS, Silliman RA, Tew WP, Walter LC, Weir AB, Wildes T. Senior adult oncology. J Natl Compr Canc Netw. 2012 Feb; 10(2):162-209.
        View in: PubMed
      63. Morrow PK, Murthy RK, Ensor JD, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN. An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. Cancer. 2012 Sep 1; 118(17):4098-104.
        View in: PubMed
      64. Rugo HS. Neoadjuvant therapy for HER2-positive early-stage breast cancer: the future is almost here. Oncology (Williston Park). 2012 Jan; 26(1):26, 28-9.
        View in: PubMed
      65. Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu S, Kerlikowske K, Ziv E. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat. 2012 Apr; 132(3):1107-18.
        View in: PubMed
      66. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62.
        View in: PubMed
      67. Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(1):13-20.
        View in: PubMed
      68. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011 Dec 15; 25(24):2559-72.
        View in: PubMed
      69. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9; 366(6):520-9.
        View in: PubMed
      70. Rugo HS, O'Shaughnessy JA, Perez EA. Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now? Clin Adv Hematol Oncol. 2011 Nov; 9(11):1-16.
        View in: PubMed
      71. Rugo HS, O'Shaughnessy JA, Perez EA. Current treatment options for metastatic breast cancer: what now? Clin Adv Hematol Oncol. 2011 Nov; 9(11 Suppl 25):1-16.
        View in: PubMed
      72. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10; 29(32):4286-93.
        View in: PubMed
      73. Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence HJ, Nikoloff M, Ziv E. Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med. 2011; 3(10):64.
        View in: PubMed
      74. Mayer EL, Baurain JF, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res. 2011 Nov 1; 17(21):6897-904.
        View in: PubMed
      75. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2796-801.
        View in: PubMed
      76. Perez EA, Mooberry S, Twelves C, Rugo HS. New frontiers and treatment paradigms for metastatic breast cancer. A Review of an adjunct symposium of the 2011 American Society of Clinical Oncology Annual Meeting, June 4, 2011 Chicago, Illinois. Clin Adv Hematol Oncol. 2011 Aug; 9(8 Suppl 20):1-15.
        View in: PubMed
      77. Rugo HS, Rosen MP. Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer. JAMA. 2011 Jul 20; 306(3):312-4.
        View in: PubMed
      78. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011 Jul 15; 17(14):4834-43.
        View in: PubMed
      79. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011 Jun; 1(1):54-67.
        View in: PubMed
      80. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 7; 104(12):1828-35.
        View in: PubMed
      81. Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol. 2011 Jun 20; 29(18):2459-65.
        View in: PubMed
      82. Greenberg S, Stopeck A, Rugo HS. Systemic treatment of early breast cancer--a biological perspective. J Surg Oncol. 2011 May 1; 103(6):619-26.
        View in: PubMed
      83. McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res. 2011 May 15; 17(10):3398-407.
        View in: PubMed
      84. Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011 Jan 15; 17(2):372-81.
        View in: PubMed
      85. Li J, Rugo HS. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer. Breast Dis. 2011; 33(2):83-92.
        View in: PubMed
      86. Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011 Feb 1; 29(4):398-405.
        View in: PubMed
      87. Albain KS, Carey L, Gradishar WJ, Gralow JR, Lipton A, Rugo H, Tripathy D, Peck S, Abair T, Pegram M. Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. Clin Breast Cancer. 2010 Dec 1; 10(6):421-39.
        View in: PubMed
      88. Mortimer JE, Barsevick AM, Bennett CL, Berger AM, Cleeland C, DeVader SR, Escalante C, Gilreath J, Hurria A, Mendoza TR, Rugo HS. Studying cancer-related fatigue: report of the NCCN scientific research committee. J Natl Compr Canc Netw. 2010 Dec; 8(12):1331-9.
        View in: PubMed
      89. Rugo HS, Kohles J, Schulman KL. Cost comparison of capecitabine in patients with breast cancer. Am J Clin Oncol. 2010 Dec; 33(6):550-6.
        View in: PubMed
      90. Greenberg S, Rugo HS. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer. Clin Breast Cancer. 2010 Sep; 10 Suppl 2:S20-9.
        View in: PubMed
      91. Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. Cancer-related fatigue. J Natl Compr Canc Netw. 2010 Aug; 8(8):904-31.
        View in: PubMed
      92. Rugo H, Brammer M, Zhang F, Lalla D. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer. 2010 Aug 1; 10(4):288-93.
        View in: PubMed
      93. Melisko ME, Goldman M, Rugo HS. Amelioration of sexual adverse effects in the early breast cancer patient. J Cancer Surviv. 2010 Sep; 4(3):247-55.
        View in: PubMed
      94. Ortmann O, Pagani O, Jones A, Maass N, Noss D, Rugo H, van de Velde C, Aapro M, Coleman R. Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Cancer Treat Rev. 2011 Apr; 37(2):97-104.
        View in: PubMed
      95. Chien AJ, Rugo HS. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf. 2010 Mar; 9(2):335-46.
        View in: PubMed
      96. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 1; 28(7):1124-30.
        View in: PubMed
      97. Greenberg S, Rugo HS. Triple-negative breast cancer: role of antiangiogenic agents. Cancer J. 2010 Jan-Feb; 16(1):33-8.
        View in: PubMed
      98. Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol. 2010 Jan 1; 28(1):77-82.
        View in: PubMed
      99. Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 2009 Dec 20; 27(36):6117-23.
        View in: PubMed
      100. Belkora JK, Loth MK, Volz S, Rugo HS. Implementing decision and communication aids to facilitate patient-centered care in breast cancer: a case study. Patient Educ Couns. 2009 Dec; 77(3):360-8.
        View in: PubMed
      101. Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA, Dickler MN. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol. 2010 Feb 1; 28(4):628-33.
        View in: PubMed
      102. Silverstein MJ, Recht A, Lagios MD, Bleiweiss IJ, Blumencranz PW, Gizienski T, Harms SE, Harness J, Jackman RJ, Klimberg VS, Kuske R, Levine GM, Linver MN, Rafferty EA, Rugo H, Schilling K, Tripathy D, Vicini FA, Whitworth PW, Willey SC. Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg. 2009 Oct; 209(4):504-20.
        View in: PubMed
      103. Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, Nabati L, Nesheiwat C, Rugo HS, Sorscher SM, Stucky-Marshal L, Todaro B, Urba S. Antiemesis. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2009 May; 7(5):572-95.
        View in: PubMed
      104. Belkora JK, Rugo HS, Moore DH, Hutton DW, Chen DF, Esserman LJ. Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis. BMC Cancer. 2009; 9:127.
        View in: PubMed
      105. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009 Jun 1; 27(16):2630-7.
        View in: PubMed
      106. Rixe O, Franco SX, Yardley DA, Johnston SR, Martin M, Arun BK, Letrent SP, Rugo HS. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2009 Nov; 64(6):1139-48.
        View in: PubMed
      107. Jo Chien A, Rugo HS. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer. Cancer Treat Res. 2009; 151:197-215.
        View in: PubMed
      108. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008 Dec 1; 14(23):7878-83.
        View in: PubMed
      109. Melisko ME, Glantz M, Rugo HS. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol. 2009 Jan; 6(1):25-33.
        View in: PubMed
      110. Belkora J, Rugo HS, Moore DH, Hutton D, Esserman L. Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates. Lancet Oncol. 2008 Jul; 9(7):602-3.
        View in: PubMed
      111. Partridge AH, Wolff AC, Marcom PK, Kaufman PA, Zhang L, Gelman R, Moore C, Lake D, Fleming GF, Rugo HS, Atkins J, Sampson E, Collyar D, Winer EP. The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Res Treat. 2009 May; 115(1):123-9.
        View in: PubMed
      112. Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol. 2008 Jul; 88(3):359-65.
        View in: PubMed
      113. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6.
        View in: PubMed
      114. Gralow J, Rugo H, Gradishar W, O'Shaughnessy JA, Jahanzeb M, Perez E, Tripathy D. Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. Clin Breast Cancer. 2008 Feb; 8(1):33-7.
        View in: PubMed
      115. Rugo HS. The importance of distant metastases in hormone-sensitive breast cancer. Breast. 2008 Jan; 17 Suppl 1:S3-8.
        View in: PubMed
      116. Rugo HS. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol. 2008 Jan; 19(1):16-27.
        View in: PubMed
      117. Wampler MA, Topp KS, Miaskowski C, Byl NN, Rugo HS, Hamel K. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. Arch Phys Med Rehabil. 2007 Aug; 88(8):1002-8.
        View in: PubMed
      118. Rugo HS. Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy. Clin Breast Cancer. 2007 Jul; 7 Suppl 1:S21-8.
        View in: PubMed
      119. Dibble SL, Luce J, Cooper BA, Israel J, Cohen M, Nussey B, Rugo H. Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial. Oncol Nurs Forum. 2007 Jul; 34(4):813-20.
        View in: PubMed
      120. Rugo HS. Hormonal therapy for advanced breast cancer. Hematol Oncol Clin North Am. 2007 Apr; 21(2):273-91.
        View in: PubMed
      121. Traina TA, Rugo HS, Dickler M. Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am. 2007 Apr; 21(2):303-19.
        View in: PubMed
      122. Lin A, Rugo HS. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol. 2007 Feb; 8(1):47-60.
        View in: PubMed
      123. Rugo H, Shtivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, Tagliaferri M, Cohen I, Shoemaker M, Tran Z, Tripathy D. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat. 2007 Sep; 105(1):17-28.
        View in: PubMed
      124. Sledge GW, Rugo HS, Burstein HJ. The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2.
        View in: PubMed
      125. Wanebo HJ, Argiris A, Bergsland E, Agarwala S, Rugo H. Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer Metastasis Rev. 2006 Jun; 25(2):279-92.
        View in: PubMed
      126. Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C, Case D, Ault K, Linker C. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant. 2006 Mar; 12(3):316-24.
        View in: PubMed
      127. Man M, Rugo H. Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical. IDrugs. 2005 Sep; 8(9):739-54.
        View in: PubMed
      128. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005 Aug 20; 23(24):5474-83.
        View in: PubMed
      129. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol. 2005 Aug 20; 23(24):5464-73.
        View in: PubMed
      130. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005 Jun; 184(6):1774-81.
        View in: PubMed
      131. Chaudhary UB, Damon LE, Rugo HS, Linker CA, Navarro W, Small EJ. High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer. Am J Clin Oncol. 2005 Apr; 28(2):130-7.
        View in: PubMed
      132. Melisko ME, Hassin F, Metzroth L, Moore DH, Brown B, Patel K, Rugo HS, Tripathy D. Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer. 2005 Apr; 6(1):45-54.
        View in: PubMed
      133. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 1; 23(4):792-9.
        View in: PubMed
      134. Lang JE, Esserman LJ, Ewing CA, Rugo HS, Lane KT, Leong SP, Hwang ES. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. J Am Coll Surg. 2004 Dec; 199(6):856-62.
        View in: PubMed
      135. Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, Linker CA. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer Chemother Pharmacol. 2004 Jun; 53(6):468-74.
        View in: PubMed
      136. Rugo HS. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist. 2004; 9 Suppl 1:43-9.
        View in: PubMed
      137. Rugo HS, Ahles T. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol. 2003 Dec; 30(6):749-62.
        View in: PubMed
      138. Rugo HS. Management of breast cancer diagnosed during pregnancy. Curr Treat Options Oncol. 2003 Apr; 4(2):165-73.
        View in: PubMed
      139. Gordon KB, Rugo HS, Duncan JL, Irvine AR, Howes EL, O'Brien JM, Carter SR. Ocular manifestations of leukemia: leukemic infiltration versus infectious process. Ophthalmology. 2001 Dec; 108(12):2293-300.
        View in: PubMed
      140. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, White M, DiPersio J, Anderson KC, Berenson J. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001 Sep 1; 19(17):3771-9.
        View in: PubMed
      141. Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001 Jul; 8(6):549-59.
        View in: PubMed
      142. Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C. NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Williston Park). 2000 Nov; 14(11A):151-61.
        View in: PubMed
      143. Damon LE, Wolf JL, Rugo HS, Gold E, Zander AR, Cassidy M, Cecchi G, Cohen N, Irwin D, Tracy M, Ries CA, Linker CA. High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant. 2000 Aug; 26(3):257-68.
        View in: PubMed
      144. Linker CA, Ries CA, Damon LE, Sayre P, Navarro W, Rugo HS, Rubin A, Case D, Crilley P, Topolsky D, Brodsky I, Zamkoff K, Wolfe JL. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant. 2000; 6(1):50-7.
        View in: PubMed
      145. Vescio RA, Wu CH, Zheng L, Sheen D, Ma H, Liu J, Stewart AK, Ballester O, Noga SJ, Rugo H, Freytes C, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Schiller GJ, White M, Jacobs C, DiPersio J, Anderson KC, Berenson JR. Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients. Bone Marrow Transplant. 2000 Jan; 25(2):153-60.
        View in: PubMed
      146. Vescio R, Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, DiPersio J, Anderson K, Berenson J. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood. 1999 Mar 15; 93(6):1858-68.
        View in: PubMed
      147. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant. 1998 Nov; 22(9):865-72.
        View in: PubMed
      148. Feldman EJ, Seiter K, Damon L, Linker C, Rugo H, Ries C, Case DC, Beer M, Ahmed T. A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia. 1997 Apr; 11(4):485-9.
        View in: PubMed
      149. Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol. 1997 Feb; 15(2):833-9.
        View in: PubMed
      150. Terdiman JP, Linker CA, Ries CA, Damon LE, Rugo HS, Ostroff JW. The role of endoscopic evaluation in patients with suspected intestinal graft-versus-host disease after allogeneic bone-marrow transplantation. Endoscopy. 1996 Oct; 28(8):680-5.
        View in: PubMed
      151. Cunningham ET, Irvine AR, Rugo HS. Bone marrow transplantation retinopathy in the absence of radiation therapy. Am J Ophthalmol. 1996 Aug; 122(2):268-70.
        View in: PubMed
      152. Damon LE, Rugo HS, Ries CA, Linker CA. Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia. Bone Marrow Transplant. 1996 Jan; 17(1):93-9.
        View in: PubMed
      153. Damon LE, Rugo HS, Ries CA, Linker CA. Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia. Leukemia. 1994 Apr; 8(4):535-41.
        View in: PubMed
      154. Rugo HS, Damon LE, Ries CA, Wolf JL, Linker CA. High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma. Prog Clin Biol Res. 1994; 389:505-11.
        View in: PubMed
      155. Linker CA, Damon LE, Ries CA, Rugo HS, Wolf JL. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update. Semin Oncol. 1993 Aug; 20(4 Suppl 4):40-8; quiz 49.
        View in: PubMed
      156. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 1993 Jan 15; 81(2):311-8.
        View in: PubMed
      157. Rugo HS, O'Hanley P, Bishop AG, Pearce MK, Abrams JS, Howard M, O'Garra A. Local cytokine production in a murine model of Escherichia coli pyelonephritis. J Clin Invest. 1992 Mar; 89(3):1032-9.
        View in: PubMed
      158. Denich K, Craiu A, Rugo H, Muralidhar G, O'Hanley P. Frequency and organization of papA homologous DNA sequences among uropathogenic digalactoside-binding Escherichia coli strains. Infect Immun. 1991 Jun; 59(6):2089-96.
        View in: PubMed
      159. O'Garra A, Stapleton G, Dhar V, Pearce M, Schumacher J, Rugo H, Barbis D, Stall A, Cupp J, Moore K, et al. Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol. 1990; 2(9):821-32.
        View in: PubMed
      160. O'Hanley P, Easaw J, Rugo H, Easaw S. Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. Am J Med. 1989 Dec; 87(6):605-13.
        View in: PubMed
      Back to TOP